Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SINOPEC CORP
00386
| (Q1)Jan 31, 2026 | (FY)Oct 31, 2025 | (Q4)Oct 31, 2025 | (Q3)Jul 31, 2025 | (Q2)Apr 30, 2025 | (Q1)Jan 31, 2025 | (FY)Oct 31, 2024 | (Q4)Oct 31, 2024 | (Q3)Jul 31, 2024 | (Q2)Apr 30, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -14.62%44.5K | -37.32%151.48K | -54.97%49.44K | -49.68%42.37K | -62.35%7.55K | 88.97%52.12K | -25.66%241.66K | -32.66%109.81K | 276.42%84.21K | -70.25%20.06K |
| Selling and administrative expenses | -8.54%33.76K | 103.80%144.47K | 67.60%35.93K | 161.55%35.82K | 157.80%35.81K | 68.81%36.91K | 5.74%70.89K | -15.23%21.44K | -10.90%13.69K | 41.14%13.89K |
| -General and administrative expense | -8.54%33.76K | 103.80%144.47K | 67.60%35.93K | 161.55%35.82K | 157.80%35.81K | 68.81%36.91K | 5.74%70.89K | -15.23%21.44K | -10.90%13.69K | 41.14%13.89K |
| Other operating expenses | -29.39%10.74K | -95.89%7.01K | -84.71%13.52K | -90.70%6.56K | -558.11%-28.26K | 166.07%15.21K | -33.82%170.77K | -35.86%88.37K | 906.98%70.52K | -89.29%6.17K |
| Operating profit | 14.62%-44.5K | 37.32%-151.48K | 54.97%-49.44K | 49.68%-42.37K | 62.35%-7.55K | -88.97%-52.12K | 25.66%-241.66K | 32.66%-109.81K | -276.42%-84.21K | 70.25%-20.06K |
| Net non-operating interest income (expenses) | -533 | 89.62%-207 | 0 | 5.61%207 | -207 | 0 | -2K | -2.19K | 196 | 0 |
| Non-operating interest income | ---- | --0 | --0 | 5.61%207 | ---- | ---- | --196 | --0 | --196 | ---- |
| Non-operating interest expense | --533 | -90.55%207 | --0 | --0 | --207 | --0 | --2.19K | --2.19K | --0 | --0 |
| Other net income (expenses) | -650K | 0 | -650K | |||||||
| Special income (charges) | ---- | --0 | --0 | --0 | --0 | ---- | ---650K | --0 | --0 | ---650K |
| -Less:Impairment of capital assets | ---- | --0 | --0 | --0 | --0 | ---- | --650K | --0 | --0 | --650K |
| Income before tax | 13.60%-45.03K | 83.03%-151.69K | 55.86%-49.44K | 49.81%-42.17K | 98.84%-7.76K | -88.97%-52.12K | -174.91%-893.65K | 31.31%-112K | -275.55%-84.02K | -893.52%-670.06K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | 13.60%-45.03K | 83.03%-151.69K | 55.86%-49.44K | 49.81%-42.17K | 98.84%-7.76K | -88.97%-52.12K | -174.91%-893.65K | 31.31%-112K | -275.55%-84.02K | -893.52%-670.06K |
| Net income continuous operations | 13.60%-45.03K | 83.03%-151.69K | 55.86%-49.44K | 49.81%-42.17K | 98.84%-7.76K | -88.97%-52.12K | -174.91%-893.65K | 31.31%-112K | -275.55%-84.02K | -893.52%-670.06K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 13.60%-45.03K | 83.03%-151.69K | 55.86%-49.44K | 49.81%-42.17K | 98.84%-7.76K | -88.97%-52.12K | -174.91%-893.65K | 31.31%-112K | -275.55%-84.02K | -893.52%-670.06K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 13.60%-45.03K | 83.03%-151.69K | 55.86%-49.44K | 49.81%-42.17K | 98.84%-7.76K | -88.97%-52.12K | -174.91%-893.65K | 31.31%-112K | -275.55%-84.02K | -893.52%-670.06K |
| Diluted earnings per share | 0 | 75.00%-0.01 | 0.00%-0.01 | 0 | 0 | 0 | -100.00%-0.04 | 0.00%-0.01 | 0 | -817.15%-0.03 |
| Basic earnings per share | 0 | 75.00%-0.01 | 0.00%-0.01 | 0 | 0 | 0 | -100.00%-0.04 | 0.00%-0.01 | 0 | -817.15%-0.03 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.